Homocysteine (Hcy) is a nonprotein α-amino acid. It is a homolog of the amino acid cysteine, differing by an additional methylene bridge (-CH 2 -). It is biosynthesized from methionine by the removal of its terminal C ε methyl group. Hcy can be recycled into methionine or converted into cysteine with the aid of B-Vitamins. Elevated Hcy levels (hyperhomocysteinemia [HHcy]) have been associated with increased cardiovascular disease and mortality rates. We present a case of acute myocardial infarction in a 25-year-old Chinese patient, associated with HHcy. His other risk factors for coronary artery disease were smoking and a moderately high low-density lipoprotein level. This case indicates that measuring plasma Hcy levels may be necessary in patients with acute coronary syndromes and premature atherosclerosis. 
introduction
Homocysteine (Hcy) is a nonprotein α-amino acid. It is a homolog of the amino acid cysteine, differing by an additional methylene bridge (-CH 2 -). It is biosynthesized from methionine by the removal of its terminal C ε methyl group. Hcy can be recycled into methionine or converted into cysteine with the aid of B-Vitamins. Elevated Hcy levels have been linked to cardiovascular disease (CVD) since 1969 [1] [2] [3] and have been implicated in promoting atherosclerotic and thrombotic vascular disease. During the past decade, the utility of Hcy in predicting a patient's risk for the developing atherothrombotic vascular disease has been evaluated in several observational studies evaluating a large number of patients. [4] [5] [6] casE rEport A 25-year-old Chinese patient was experienced severe midsternal chest pain, accompanied by sweating, nausea, and shortness of breath for 2 h. An electrocardiogram was done in the local hospital, and it revealed ST-segment elevation in leads V1-V5 [ Figure 1a ]. He was immediately transferred to our emergency room by an ambulance. Emergent coronary angiography was performed and it revealed a completely occluded proximal left anterior descending (LAD) artery, a long lesion at the middle segment of the left circumflex artery (LCx) with focal stenosis (70%) and a long lesion at the middle segment of the right coronary artery with focal stenosis (60%) [ Figure 2a -c]. Coronary angioplasty and stent implantation in the LAD were successfully performed without any complications [ Figure 2d ]. The patient was transferred into the coronary care unit, and he reported a significant reduction in chest pain after the percutaneous coronary intervention (PCI) procedure, with a corresponding drop in the ST-segment elevation [ Figure 1b ]. He had a history of moderate smoking (about 10 cigarette/day) and hyperlipidemia, but his family history was negative for premature CVD. 
discussion
Epidemiological studies and increasing data indicate that hyperhomocysteinemia (HHcy) is an important risk factor for the development of vascular disease. HHcy is also an independent, modifiable risk factor for ischemic heart diseases and thrombosis. [2] Several studies showed a positive correlation between plasma Hcy concentrations and ischemic heart disease. [7] Recently, Page et al. demonstrated that HHcy was associated with increased coronary artery diseases in postmenopausal women. [8] Other researchers suggested that >50% of children with the genetic disorder homocystinuria die of the premature vascular disease. [1, 9] It is noteworthy that 30%-35% of individuals with CVD present normocolesterolemia, but >40% of patients with primary disease involving the coronary artery, cerebrovascular, or peripheral vascular have HHcy. [10] Humphrey et al. did a systematic review and meta-analysis regarding Hcy levels and the incidence of coronary heart disease (CHD), and they concluded that each increase of 5 μmol/L in Hcy level increases the risk of CHD events by approximately 20%, independently of traditional CHD risk factors. [11] Bozkurt et al. suggested that HHcy is an independent risk factor for coronary artery disease similar to major risk factors in the sense that it increases the risk of 3.69 fold. [12] There were reports that a decrease of 3-5 μmol/L in Hcy can reduce the rates of vascular event. [13, 14] It has been reported that in acute coronary syndrome cases, there is more extensive ischemic myocardial injury and more late cardiac events in patients who have associated with high Hcy plasma levels. [15] Recently, Davidson et al. performed a dual-institution, retrospective study of consecutive patients aged ≤35 years who presented with the acute coronary syndrome and underwent coronary angiography. They concluded that very young patients with acute coronary syndrome tend to be obese, with a high prevalence of smoking and hyperlipidemia. [16] In regard to our patient, it is quite unusual for a 25-year-old Chinese person to suffer from multivessel coronary artery disease with acute MI, even when taking into account the traditional risk factors mentioned in his history. However, the patient had a moderate HHcy level of 54 μmol/L (the range for moderate HHcy is 30-100 μmol/L). Considering "each increase of 5 μmol/L in Hcy level increases the risk of CHD events by approximately 20%," with the moderate HHcy superimposed on the patient's risk factors, we believe that this facilitated the development of the atherosclerotic disorder in our patient. After 1 month of dietary supplementation with folic acid and Vitamin B6 and B12, his Hcy level was dropped to 37.6 μmol/L, and he is currently in follow-up.
The mechanisms by which elevated Hcy levels impair vascular function are not completely understood. Investigations have revealed several potential mechanisms including impairment of endothelial function, oxidation of low-density lipids, increased monocyte adhesion to the vessel wall, increased lipid uptake and retention, activation of the inflammatory pathway, stimulatory effects on smooth-muscle proliferation, and thrombotic tendency mediated by activation of coagulation factors and platelet dysfunction. Further investigation is needed to study the atherogenic and thrombogenic mechanisms of Hcy and the effects of dietary supplementation of folic acid and Vitamin B6 and B12 on its pathogenesis.
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